Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sorafenib Tosylate

FDA-approved product (tablet, oral), marketed as Nexavar, Sorafenib Tosylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Sorafenib Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Hepatocellular carcinoma
  • Papillary renal cell carcinoma
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sorafenib Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sorafenib Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

    NCT01004978 · start 2009-10-28

    Registered record
    Registry ID
    NCT01004978
    Conditions
    Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma
    Interventions
    Cisplatin; Computed Tomography; Doxorubicin Hydrochloride; Doxorubicin-Eluting Beads; Laboratory Biomarker Analysis; Magnetic Resonance Imaging; Mitomycin; Pharmacological Study; Placebo Administration; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10-28
    Completion
    2022-12-21
    Enrolment
    235

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma
    InterventionCisplatin; Computed Tomography; Doxorubicin Hydrochloride; Doxorubicin-Eluting Beads +6 more
    PhasePhase 3
    Registry statusCompleted

  • Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

    NCT00826540 · start 2009-09

    Registered record
    Registry ID
    NCT00826540
    Conditions
    Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer
    Interventions
    sorafenib tosylate; bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09
    Completion
    2014-02
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer
    Interventionsorafenib tosylate; bevacizumab
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

    NCT00981162 · start 2009-08

    Registered record
    Registry ID
    NCT00981162
    Conditions
    Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    sorafenib tosylate; everolimus; laboratory biomarker analysis; pharmacogenomic studies; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2012-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer +1 more
    Interventionsorafenib tosylate; everolimus; laboratory biomarker analysis; pharmacogenomic studies +1 more
    PhasePhase 1
    Registry statusCompleted

  • Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    NCT00867321 · start 2009-04

    Registered record
    Registry ID
    NCT00867321
    Conditions
    Liver Cancer
    Interventions
    bevacizumab; sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cancer
    Interventionbevacizumab; sorafenib tosylate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

    NCT00822848 · start 2009-02

    Registered record
    Registry ID
    NCT00822848
    Conditions
    Sarcoma
    Interventions
    epirubicin hydrochloride; ifosfamide; sorafenib tosylate; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery; hypofractionated radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2013-04-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventionepirubicin hydrochloride; ifosfamide; sorafenib tosylate; immunoenzyme technique +6 more
    PhasePhase 1
    Registry statusCompleted

  • Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

    NCT00846131 · start 2009-02

    Registered record
    Registry ID
    NCT00846131
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Sorafenib; Yttrium-90 (Y-90)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2016-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionSorafenib; Yttrium-90 (Y-90)
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer

    NCT00828074 · start 2008-11

    Registered record
    Registry ID
    NCT00828074
    Conditions
    Breast Cancer
    Interventions
    sorafenib tosylate; vinorelbine ditartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2014-04
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionsorafenib tosylate; vinorelbine ditartrate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    NCT00754923 · start 2008-10

    Registered record
    Registry ID
    NCT00754923
    Conditions
    Lung Cancer
    Interventions
    sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2012-04
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventionsorafenib
    PhasePhase 2
    Registry statusTerminated

  • Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    NCT00687674 · start 2008-08

    Registered record
    Registry ID
    NCT00687674
    Conditions
    Multiple Myeloma and Plasma Cell Neoplasm
    Interventions
    dexamethasone; sorafenib tosylate; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2011-11
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma and Plasma Cell Neoplasm
    Interventiondexamethasone; sorafenib tosylate; Lenalidomide
    PhasePhase 1
    Registry statusTerminated

  • Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

    NCT00703638 · start 2008-05

    Registered record
    Registry ID
    NCT00703638
    Conditions
    Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
    Interventions
    cisplatin; pemetrexed disodium; sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-05
    Completion
    2010-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer +4 more
    Interventioncisplatin; pemetrexed disodium; sorafenib
    PhasePhase 1
    Registry statusCompleted

  • Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

    NCT00635791 · start 2008-03

    Registered record
    Registry ID
    NCT00635791
    Conditions
    Malignant Solid Tumour; Renal Cell Carcinoma; Non Small Cell Lung Carcinoma
    Interventions
    Sorafenib; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03
    Completion
    2012-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Tumour; Renal Cell Carcinoma; Non Small Cell Lung Carcinoma
    InterventionSorafenib; Vorinostat
    PhasePhase 1
    Registry statusCompleted

  • PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

    NCT00589550 · start 2008-02

    Registered record
    Registry ID
    NCT00589550
    Conditions
    Kidney Cancer
    Interventions
    PEG-interferon alfa-2b; Sorafenib; gene expression analysis; polymerase chain reaction; reverse transcriptase-polymerase chain reaction; flow cytometry; immunoenzyme technique; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2008-02
    Completion
    2009-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    InterventionPEG-interferon alfa-2b; Sorafenib; gene expression analysis; polymerase chain reaction +4 more
    PhasePhase 1
    Registry statusTerminated

  • Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

    NCT00565968 · start 2007-10

    Registered record
    Registry ID
    NCT00565968
    Conditions
    Melanoma (Skin)
    Interventions
    melphalan; sorafenib tosylate; gene expression analysis; protein expression analysis; western blotting; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-10
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin)
    Interventionmelphalan; sorafenib tosylate; gene expression analysis; protein expression analysis +2 more
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

    NCT00573690 · start 2007-09

    Registered record
    Registry ID
    NCT00573690
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    carboplatin; cisplatin; etoposide; pemetrexed disodium; sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    2011-02
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventioncarboplatin; cisplatin; etoposide; pemetrexed disodium +1 more
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

    NCT00281957 · start 2007-08

    Registered record
    Registry ID
    NCT00281957
    Conditions
    Recurrent Melanoma; Stage IV Melanoma
    Interventions
    sorafenib tosylate; tipifarnib; temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2011-01
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Melanoma; Stage IV Melanoma
    Interventionsorafenib tosylate; tipifarnib; temsirolimus
    PhasePhase 2
    Registry statusCompleted